V_15(Gy) as a predictor of asymptomatic radiation pneumonitis in patients with lung cancer: A retrospective dosimetric analysis

Abstract

Purpose: This study aimed to investigate the dose dependency of asymptomatic radiation pneumonitis (aRP) in patients with lung cancer following radiotherapy, focusing on the predictive value of dosimetric parameters.

Methods: This study included 72 patients with primary lung cancer who underwent radiotherapy between January 2019 and June 2022. The patients were divided into an aRP group (n = 30) and a non-RP group (n = 42). The physical dose was converted to an equivalent dose using the Linear-Quadratic (LQ) model, with an α/β value of 3. Three lung structures were defined, and the corresponding dose-volume histogram parameters were collected. The Mann–Whitney U test was used to compare dose parameters between the two groups, and multivariate logistic regression was performed to remove correlations among different parameters. A logistic function and receiver operating characteristic curve were constructed to predict aRP. This study analyzed the impact of different clinical characteristics on the aRP incidence.

Results: The lungs-planning target volume (PTV) V_15(Gy) was ultimately identified as the best predictive parameter. Significant dose–response relationships were observed, with V_15(Gy) achieving an area under the curve of 0.666 ± 0.067 (P = 0.017). The optimal cutoff value for lungs-PTV V_15(Gy) was 21.1%, below which the incidence of aRP decreased significantly. Immunotherapy has been identified as an independent risk factor for aRP.

Conclusion: The occurrence of aRP in patients with lung cancer after radiotherapy has a clear dose dependency, with lungs-PTV, V_15(Gy) being the best dose parameter for prediction, and the optimal cutoff value based on this study was 21.1%.

Keywords

Dosimetry / Logistic Models / Lung Neoplasms / Radiation Pneumonitis / Radiotherapy

References

[1] Ullah T, Patel H, Pena GM, et al. A contemporary review of radiation pneumonitis. Curr Opin Pulm Med. 2020; 26(4): 321-325.

[2] Jain V, Berman AT. Radiation Pneumonitis: Old Problem, New Tricks. Cancers (Basel). 2018; 10(7): 222.

[3] Yafeng L, Jing W, Jiawei Z, et al. Construction and Verification of a Radiation Pneumonia Prediction Model Based on Multiple Parameters. Cancer Control. 2021; 28: 1399522577.

[4] Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999; 45(2): 323-329.

[5] Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys. 2006; 65(4): 1075-1086.

[6] Farr KP, Khalil AA, Knap MM, et al. Development of radiation pneumopathy and generalised radiological changes after radiotherapy are independent negative prognostic factors for survival in non-small cell lung cancer patients. Radiother Oncol. 2013; 107(3): 382-388.

[7] Tsujino K, Hashimoto T, Shimada T, et al. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. J Thorac Oncol. 2014; 9(7): 983-990.

[8] Chen F, Niu J, Wang M, et al. Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy. J Transl Med. 2023; 21(1): 368.

[9] Chun SG, Hu C, Choy H, et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017; 35(1): 56-62.

[10] Zhou C, Yu J. Chinese expert consensus on diagnosis and treatment of radiation pneumonitis. Precis Radiat Oncol. 2022; 3(6): 262-271

[11] Kong FS, Moiseenko V, Zhao J, et al. Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? Int J Radiat Oncol Biol Phys. 2021; 110(1): 172-187.

[12] Singh G, Oinam AS, Kamal R, et al. Voxel based BED and EQD2 Evaluation of the Radiotherapy Treatment Plan. J Med Phys. 2018; 43(3): 155-161.

[13] Moiseenko V, Marks LB, Grimm J, et al. A Primer on Dose-Response Data Modeling in Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021; 110(1): 11-20.

[14] Schallenkamp JM, Miller RC, Brinkmann DH, et al. Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat Oncol Biol Phys. 2007; 67(2): 410-416.

[15] Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys. 2005; 63(1): 5-24.

[16] Gopal R, Tucker SL, Komaki R, et al. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys. 2003; 56(1): 106-113.

[17] Krafft SP, Rao A, Stingo F, et al. The utility of quantitative CT radiomics features for improved prediction of radiation pneumonitis. Med Phys. 2018; 45(11): 5317-5324.

[18] Wang W, Xu Y, Schipper M, et al. Effect of normal lung definition on lung dosimetry and lung toxicity prediction in radiation therapy treatment planning. Int J Radiat Oncol Biol Phys. 2013; 86(5): 956-963.

[19] Kabolizadeh P, Kalash R, Huq MS, et al. Dosimetric definitions of total lung volumes in calculating parameters predictive for radiation-induced pneumonitis. Am J Clin Oncol. 2015; 38(4): 401-404.

[20] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015; 16(2): 187-199.

[21] Jenkins P, Watts J. An Improved Model for Predicting Radiation Pneumonitis Incorporating Clinical and Dosimetric Variables. Int J Radiat Oncol Biol Phys. 2011;; 80(4): 1023-1029.

[22] De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Radiother Oncol. 2005; 77(1): 5-10.

[23] Hernando M, Marks L, Bentel G, et al. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001; 51(3): 650-659.

[24] Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer–a systematic review. Radiother Oncol. 2004; 71(2): 127-138.

[25] Nestle U, De Ruysscher D, Ricardi U, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018; 127(1): 1-5.

[26] Meng Y, Yang H, Wang W, et al. Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients. Radiat Oncol. 2019; 14(1): 7.

[27] Faivre-Finn C, Vicente D, Kurata T, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. J Thorac Oncol. 2021; 16(5): 860-867.

[28] Aiad M, Fresco K, Prenatt Z, et al. Comparison of Pneumonitis Rates and Severity in Patients With Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy. Curēus (Palo Alto, CA). 2022; 14(6): e25665.

[29] Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124(2): 687-695.

[30] Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20): 1919-1929.

RIGHTS & PERMISSIONS

2025 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.